Total Payments
$58,719
2024 Payments
$31,487
Companies
10
Transactions
38
Medicare Patients
821
Medicare Billing
$154,237
Payment Breakdown by Category
Consulting$47,998 (81.7%)
Travel$4,988 (8.5%)
Other$4,200 (7.2%)
Food & Beverage$1,481 (2.5%)
Research$51.90 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $47,998 | 10 | 81.7% |
| Travel and Lodging | $4,988 | 7 | 8.5% |
| Honoraria | $4,200 | 1 | 7.2% |
| Food and Beverage | $1,481 | 19 | 2.5% |
| Unspecified | $51.90 | 1 | 0.1% |
Payments by Type
General
$58,667
37 transactions
Research
$51.90
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADC Therapeutics America, Inc. | $47,643 | 27 | $0 (2024) |
| Genentech USA, Inc. | $4,790 | 3 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,840 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,943 | 1 | $0 (2023) |
| Seagen Inc. | $1,225 | 1 | $0 (2022) |
| Gilead Sciences, Inc. | $99.00 | 1 | $0 (2024) |
| Seattle Genetics, Inc. | $85.41 | 1 | $0 (2018) |
| Eli Lilly and Company | $51.90 | 1 | $0 (2023) |
| ABBVIE INC. | $23.83 | 1 | $0 (2024) |
| BeiGene USA, Inc. | $18.42 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,487 | 22 | ADC Therapeutics America, Inc. ($26,759) |
| 2023 | $13,662 | 6 | ADC Therapeutics America, Inc. ($10,407) |
| 2022 | $13,467 | 8 | ADC Therapeutics America, Inc. ($10,477) |
| 2021 | $18.42 | 1 | BeiGene USA, Inc. ($18.42) |
| 2018 | $85.41 | 1 | Seattle Genetics, Inc. ($85.41) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
| 10/09/2024 | Genentech USA, Inc. | Polivy (Biological), Columvi, Lunsumio | Consulting Fee | Cash or cash equivalent | $1,765.00 | General |
| Category: BioOncology | ||||||
| 09/27/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $346.69 | General |
| 09/27/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $120.03 | General |
| 09/27/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $60.02 | General |
| 09/27/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $50.01 | General |
| 09/27/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $43.01 | General |
| 09/27/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.01 | General |
| 09/23/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,155.37 | General |
| 09/17/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $99.00 | General |
| Category: COVID-19 | ||||||
| 09/12/2024 | ADC Therapeutics America, Inc. | — | Honoraria | Cash or cash equivalent | $4,200.00 | General |
| 09/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,840.00 | General |
| 07/29/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $888.53 | General |
| 07/25/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $69.66 | General |
| 04/26/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,400.00 | General |
| 04/04/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,212.30 | General |
| 03/08/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $277.12 | General |
| 03/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $146.08 | General |
| 03/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $68.50 | General |
| 03/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $57.29 | General |
| 03/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $40.27 | General |
| 12/10/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $142.71 | General |
| 12/09/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $64.47 | General |
| 12/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $51.90 | Research |
| Study: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | Eli Lilly and Company | $51.90 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 402 | 705 | $280,962 | $68,940 |
| 2022 | 6 | 281 | 570 | $202,960 | $52,842 |
| 2021 | 5 | 124 | 271 | $93,445 | $26,384 |
| 2020 | 1 | 14 | 72 | $20,304 | $6,070 |
Total Patients
821
Total Services
1,618
Medicare Billing
$154,237
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 184 | $53,923 | $17,406 | 32.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 75 | 144 | $63,644 | $14,892 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 94 | 141 | $46,416 | $9,553 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 83 | $39,507 | $9,440 | 23.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 39 | $22,113 | $5,000 | 22.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 37 | 37 | $21,423 | $4,717 | 22.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $19,107 | $4,595 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 36 | 44 | $14,829 | $3,337 | 22.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 59 | 254 | $73,612 | $20,375 | 27.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 51 | 120 | $48,480 | $13,040 | 26.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 60 | 60 | $34,560 | $7,738 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 55 | 77 | $23,114 | $5,345 | 23.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 31 | $17,481 | $4,822 | 27.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 28 | 28 | $5,713 | $1,522 | 26.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 45 | 150 | $42,726 | $12,317 | 28.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 22 | 46 | $17,464 | $5,409 | 31.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $15,195 | $3,825 | 25.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 18 | $9,906 | $2,866 | 28.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 29 | $8,154 | $1,968 | 24.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 72 | $20,304 | $6,070 | 29.9% |
About Dr. Emily Ayers, MD
Dr. Emily Ayers, MD is a Hematology healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/02/2014. The National Provider Identifier (NPI) number assigned to this provider is 1033529896.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emily Ayers, MD has received a total of $58,719 in payments from pharmaceutical and medical device companies, with $31,487 received in 2024. These payments were reported across 38 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($47,998).
As a Medicare-enrolled provider, Ayers has provided services to 821 Medicare beneficiaries, totaling 1,618 services with total Medicare billing of $154,237. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Charlottesville, VA
- Active Since 05/02/2014
- Last Updated 08/08/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1033529896
Products in Payments
- CALQUENCE (Drug) $1,943
- POLIVY (Biological) $1,765
- Polivy (Biological) $1,765
- ADCETRIS (Biological) $1,310
- Lunsumio (Biological) $1,260
- Veklury (Drug) $99.00
- VENCLEXTA (Drug) $23.83
- BRUKINSA (Drug) $18.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Charlottesville
B. Gail Macik, Md, MD
Hematology — Payments: $115,184
Hematology $115,184
Valery Kogler, M.d, M.D
Hematology — Payments: $554.37
Hematology $554.37
Nadine Aguilera, M.d, M.D
Hematology — Payments: $66.58
Hematology $66.58
John Densmore, M.d, M.D
Hematology — Payments: $32.34
Hematology $32.34
Stephanie Good, Pa, PA
Hematology — Payments: $27.81
Hematology $27.81